| pubmed-article:7536681 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7536681 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:7536681 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:7536681 | lifeskim:mentions | umls-concept:C0079460 | lld:lifeskim |
| pubmed-article:7536681 | lifeskim:mentions | umls-concept:C0026473 | lld:lifeskim |
| pubmed-article:7536681 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
| pubmed-article:7536681 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:7536681 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7536681 | pubmed:dateCreated | 1995-5-25 | lld:pubmed |
| pubmed-article:7536681 | pubmed:abstractText | The influence of colony-stimulating factors (CSFs) on the monocyte functions of 32 patients with refractory testicular cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT) was tested. Eight patients were treated as a control group without CSF therapy, 12 patients received recombinant human granulocyte-macrophage-CSF (rhGM-CSF), and 12 patients received recombinant human granulocyte-CSF (rhG-CSF). For the assessment of monocyte activation induced by CSF expression of major histocompatibility complex (MHC) class I and II antigens, production of tumor necrosis factor (TNF) and monocyte-mediated cytotoxicity against tumor cell targets were chosen. Monocytes from patients with GM-CSF therapy showed a significant increase in MHC class I and II antigen expression as compared to patients without CSF treatment (p < 0.001). A significant increase in the expression of MHC class I was seen in monocytes from patients under G-CSF treatment, whereas no change of class II antigens was noticed. Production of TNF and monocyte-mediated cytotoxicity against U937 tumor cells was significantly increased in monocytes derived from patients receiving GM-CSF, as compared to those from the control group, while no effect was detectable in monocytes from patients with G-CSF therapy. However, after in vitro stimulation with interferon-gamma (IFN-gamma), monocytes derived from GM-CSF as well as from G-CSF treated patients responded with a significantly higher TNF-production and cytotoxicity than monocytes from control patients. | lld:pubmed |
| pubmed-article:7536681 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7536681 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7536681 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7536681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7536681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7536681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7536681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7536681 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7536681 | pubmed:month | May | lld:pubmed |
| pubmed-article:7536681 | pubmed:issn | 0301-472X | lld:pubmed |
| pubmed-article:7536681 | pubmed:author | pubmed-author:WagnerAA | lld:pubmed |
| pubmed-article:7536681 | pubmed:author | pubmed-author:LinkeschWW | lld:pubmed |
| pubmed-article:7536681 | pubmed:author | pubmed-author:ZielinskiC... | lld:pubmed |
| pubmed-article:7536681 | pubmed:author | pubmed-author:WiltschkeCC | lld:pubmed |
| pubmed-article:7536681 | pubmed:author | pubmed-author:KrainerMM | lld:pubmed |
| pubmed-article:7536681 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7536681 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:7536681 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7536681 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7536681 | pubmed:pagination | 402-6 | lld:pubmed |
| pubmed-article:7536681 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:meshHeading | pubmed-meshheading:7536681-... | lld:pubmed |
| pubmed-article:7536681 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7536681 | pubmed:articleTitle | Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. | lld:pubmed |
| pubmed-article:7536681 | pubmed:affiliation | Clinical Division of Oncology, University Hospital, Vienna, Austria. | lld:pubmed |
| pubmed-article:7536681 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7536681 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7536681 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7536681 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7536681 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7536681 | lld:pubmed |
